Clinical evaluation of radiotherapy for no hypopharyngeal cancer

Yoshiyuki Shioyama, Katsumasa Nakamura, Tomonari Sasaki, Saiji Ohoga, Madoka Saku, Yusuke Urashima, Tadamasa Yoshitake, Hiroshi Honda, Yuichirou Kuratomi, Torahiko Nakashima, Shizuo Komune, Kenichi Jingu, Hiromi Terashima

研究成果: ジャーナルへの寄稿記事

抄録

Seventy-five hypopharyngeal cancer patients without lymph-node metastasis, treated with radiotherapy at Kyushu University Hospital from 1976 through 2003, were evaluated. T category was 10 in T1, 41 in T2, 13 in T3, and 11 in T4. Median total doses of radiation therapy were 62.5Gy (range : 60-74Gy) in radical intent, and 30Gy (28.5-41.4Gy) in the preoperative setting. Patient selection as to radical radiotherapy or preoperative irradiation plus surgery was performed at 30-40Gy by an oncologist of head and neck surgery and a radiation oncologist, according to the tumor response to radiation therapy. Most patients were treated with radiotherapy combined with concurrent chemotherapy including 5-fluorouracil (5-FU) and Vitamin A. As the result, radical radiotherapy was selected for 48 patients (T1, 9; T2, 30; T3, 4; T4, 5), and preoperative irradiation plus surgery was selected for 27 patients (T1, 1; T2, 11; T3, 9; T4, 6) For 75 T1-4 cancer patients, the 5-year overall and cause-specific survival rates were 62% and 75%, respectively. The 5-year cause-specific survival (5y-CSS) rates were 100% for T1, 85% for T2, 83% for T3, and 30% for T4. For patients with T1-2 cancers, there was no significant difference in survival between the RT+Surgery group and the RT group; 5-year CSS was 92% vs. 85%, respectively. In the RT group, however, the prognosis of patients with T3-4 cancers (5-year CSS : 29%) was significantly poor compared with that of patients with T1-2 cancers. The 5-year local progression-free survival with laryngeal preservation was 65% in T1-2 cancers, 6% in T3-4 cancers, and 45% in all patients. Radiotherapy has an advantage for the preservation of laryngeal function compared with surgery. For stage I-II cancers, therefore, radiotherapy should be first considered as a radical treatment option. For T3-4 cancers, however, the combination of radiotherapy and surgery was thought to be proper treatment.

元の言語英語
ページ(範囲)563-569
ページ数7
ジャーナルToukeibu Gan
30
発行部数4
DOI
出版物ステータス出版済み - 1 1 2004

Fingerprint

Hypopharyngeal Neoplasms
Radiotherapy
Neoplasms
Survival Rate
Vitamin A
Fluorouracil
Patient Selection
Disease-Free Survival
Neck
Lymph Nodes
Head
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Oncology

これを引用

Shioyama, Y., Nakamura, K., Sasaki, T., Ohoga, S., Saku, M., Urashima, Y., ... Terashima, H. (2004). Clinical evaluation of radiotherapy for no hypopharyngeal cancer. Toukeibu Gan, 30(4), 563-569. https://doi.org/10.5981/jjhnc.30.563

Clinical evaluation of radiotherapy for no hypopharyngeal cancer. / Shioyama, Yoshiyuki; Nakamura, Katsumasa; Sasaki, Tomonari; Ohoga, Saiji; Saku, Madoka; Urashima, Yusuke; Yoshitake, Tadamasa; Honda, Hiroshi; Kuratomi, Yuichirou; Nakashima, Torahiko; Komune, Shizuo; Jingu, Kenichi; Terashima, Hiromi.

:: Toukeibu Gan, 巻 30, 番号 4, 01.01.2004, p. 563-569.

研究成果: ジャーナルへの寄稿記事

Shioyama, Y, Nakamura, K, Sasaki, T, Ohoga, S, Saku, M, Urashima, Y, Yoshitake, T, Honda, H, Kuratomi, Y, Nakashima, T, Komune, S, Jingu, K & Terashima, H 2004, 'Clinical evaluation of radiotherapy for no hypopharyngeal cancer', Toukeibu Gan, 巻. 30, 番号 4, pp. 563-569. https://doi.org/10.5981/jjhnc.30.563
Shioyama, Yoshiyuki ; Nakamura, Katsumasa ; Sasaki, Tomonari ; Ohoga, Saiji ; Saku, Madoka ; Urashima, Yusuke ; Yoshitake, Tadamasa ; Honda, Hiroshi ; Kuratomi, Yuichirou ; Nakashima, Torahiko ; Komune, Shizuo ; Jingu, Kenichi ; Terashima, Hiromi. / Clinical evaluation of radiotherapy for no hypopharyngeal cancer. :: Toukeibu Gan. 2004 ; 巻 30, 番号 4. pp. 563-569.
@article{53466c40ac644833a797181f0dac6c66,
title = "Clinical evaluation of radiotherapy for no hypopharyngeal cancer",
abstract = "Seventy-five hypopharyngeal cancer patients without lymph-node metastasis, treated with radiotherapy at Kyushu University Hospital from 1976 through 2003, were evaluated. T category was 10 in T1, 41 in T2, 13 in T3, and 11 in T4. Median total doses of radiation therapy were 62.5Gy (range : 60-74Gy) in radical intent, and 30Gy (28.5-41.4Gy) in the preoperative setting. Patient selection as to radical radiotherapy or preoperative irradiation plus surgery was performed at 30-40Gy by an oncologist of head and neck surgery and a radiation oncologist, according to the tumor response to radiation therapy. Most patients were treated with radiotherapy combined with concurrent chemotherapy including 5-fluorouracil (5-FU) and Vitamin A. As the result, radical radiotherapy was selected for 48 patients (T1, 9; T2, 30; T3, 4; T4, 5), and preoperative irradiation plus surgery was selected for 27 patients (T1, 1; T2, 11; T3, 9; T4, 6) For 75 T1-4 cancer patients, the 5-year overall and cause-specific survival rates were 62{\%} and 75{\%}, respectively. The 5-year cause-specific survival (5y-CSS) rates were 100{\%} for T1, 85{\%} for T2, 83{\%} for T3, and 30{\%} for T4. For patients with T1-2 cancers, there was no significant difference in survival between the RT+Surgery group and the RT group; 5-year CSS was 92{\%} vs. 85{\%}, respectively. In the RT group, however, the prognosis of patients with T3-4 cancers (5-year CSS : 29{\%}) was significantly poor compared with that of patients with T1-2 cancers. The 5-year local progression-free survival with laryngeal preservation was 65{\%} in T1-2 cancers, 6{\%} in T3-4 cancers, and 45{\%} in all patients. Radiotherapy has an advantage for the preservation of laryngeal function compared with surgery. For stage I-II cancers, therefore, radiotherapy should be first considered as a radical treatment option. For T3-4 cancers, however, the combination of radiotherapy and surgery was thought to be proper treatment.",
author = "Yoshiyuki Shioyama and Katsumasa Nakamura and Tomonari Sasaki and Saiji Ohoga and Madoka Saku and Yusuke Urashima and Tadamasa Yoshitake and Hiroshi Honda and Yuichirou Kuratomi and Torahiko Nakashima and Shizuo Komune and Kenichi Jingu and Hiromi Terashima",
year = "2004",
month = "1",
day = "1",
doi = "10.5981/jjhnc.30.563",
language = "English",
volume = "30",
pages = "563--569",
journal = "Japanese Journal of Head and Neck Cancer",
issn = "1349-5747",
publisher = "Nihon Tokeibu Gan Gakkai",
number = "4",

}

TY - JOUR

T1 - Clinical evaluation of radiotherapy for no hypopharyngeal cancer

AU - Shioyama, Yoshiyuki

AU - Nakamura, Katsumasa

AU - Sasaki, Tomonari

AU - Ohoga, Saiji

AU - Saku, Madoka

AU - Urashima, Yusuke

AU - Yoshitake, Tadamasa

AU - Honda, Hiroshi

AU - Kuratomi, Yuichirou

AU - Nakashima, Torahiko

AU - Komune, Shizuo

AU - Jingu, Kenichi

AU - Terashima, Hiromi

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Seventy-five hypopharyngeal cancer patients without lymph-node metastasis, treated with radiotherapy at Kyushu University Hospital from 1976 through 2003, were evaluated. T category was 10 in T1, 41 in T2, 13 in T3, and 11 in T4. Median total doses of radiation therapy were 62.5Gy (range : 60-74Gy) in radical intent, and 30Gy (28.5-41.4Gy) in the preoperative setting. Patient selection as to radical radiotherapy or preoperative irradiation plus surgery was performed at 30-40Gy by an oncologist of head and neck surgery and a radiation oncologist, according to the tumor response to radiation therapy. Most patients were treated with radiotherapy combined with concurrent chemotherapy including 5-fluorouracil (5-FU) and Vitamin A. As the result, radical radiotherapy was selected for 48 patients (T1, 9; T2, 30; T3, 4; T4, 5), and preoperative irradiation plus surgery was selected for 27 patients (T1, 1; T2, 11; T3, 9; T4, 6) For 75 T1-4 cancer patients, the 5-year overall and cause-specific survival rates were 62% and 75%, respectively. The 5-year cause-specific survival (5y-CSS) rates were 100% for T1, 85% for T2, 83% for T3, and 30% for T4. For patients with T1-2 cancers, there was no significant difference in survival between the RT+Surgery group and the RT group; 5-year CSS was 92% vs. 85%, respectively. In the RT group, however, the prognosis of patients with T3-4 cancers (5-year CSS : 29%) was significantly poor compared with that of patients with T1-2 cancers. The 5-year local progression-free survival with laryngeal preservation was 65% in T1-2 cancers, 6% in T3-4 cancers, and 45% in all patients. Radiotherapy has an advantage for the preservation of laryngeal function compared with surgery. For stage I-II cancers, therefore, radiotherapy should be first considered as a radical treatment option. For T3-4 cancers, however, the combination of radiotherapy and surgery was thought to be proper treatment.

AB - Seventy-five hypopharyngeal cancer patients without lymph-node metastasis, treated with radiotherapy at Kyushu University Hospital from 1976 through 2003, were evaluated. T category was 10 in T1, 41 in T2, 13 in T3, and 11 in T4. Median total doses of radiation therapy were 62.5Gy (range : 60-74Gy) in radical intent, and 30Gy (28.5-41.4Gy) in the preoperative setting. Patient selection as to radical radiotherapy or preoperative irradiation plus surgery was performed at 30-40Gy by an oncologist of head and neck surgery and a radiation oncologist, according to the tumor response to radiation therapy. Most patients were treated with radiotherapy combined with concurrent chemotherapy including 5-fluorouracil (5-FU) and Vitamin A. As the result, radical radiotherapy was selected for 48 patients (T1, 9; T2, 30; T3, 4; T4, 5), and preoperative irradiation plus surgery was selected for 27 patients (T1, 1; T2, 11; T3, 9; T4, 6) For 75 T1-4 cancer patients, the 5-year overall and cause-specific survival rates were 62% and 75%, respectively. The 5-year cause-specific survival (5y-CSS) rates were 100% for T1, 85% for T2, 83% for T3, and 30% for T4. For patients with T1-2 cancers, there was no significant difference in survival between the RT+Surgery group and the RT group; 5-year CSS was 92% vs. 85%, respectively. In the RT group, however, the prognosis of patients with T3-4 cancers (5-year CSS : 29%) was significantly poor compared with that of patients with T1-2 cancers. The 5-year local progression-free survival with laryngeal preservation was 65% in T1-2 cancers, 6% in T3-4 cancers, and 45% in all patients. Radiotherapy has an advantage for the preservation of laryngeal function compared with surgery. For stage I-II cancers, therefore, radiotherapy should be first considered as a radical treatment option. For T3-4 cancers, however, the combination of radiotherapy and surgery was thought to be proper treatment.

UR - http://www.scopus.com/inward/record.url?scp=85009643112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009643112&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.30.563

DO - 10.5981/jjhnc.30.563

M3 - Article

VL - 30

SP - 563

EP - 569

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

SN - 1349-5747

IS - 4

ER -